ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Safety

FDA Warns Largest Indian Drugmaker

by K.V. Venkatasubramanian
January 4, 2016 | APPEARED IN VOLUME 94, ISSUE 1

FDA last month issued a warning to India’s largest drugmaker, Sun Pharmaceutical Industries, for violating manufacturing standards at its Halol plant, in the western state of Gujarat. In part, FDA says, the company “failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile.” The Halol facility is among the largest and important for Sun Pharma and produces multiple formulations, including injectable products, which are mainly exported to the U.S., its largest market, which makes up about 15% of its sales. In a statement, the company says it has been implementing corrective measures since September 2014, when FDA first inspected the facility.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment